Teleflex’s (TFX) “Overweight” Rating Reaffirmed at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Teleflex (NYSE:TFX) in a report issued on Friday,Benzinga reports. Piper Sandler currently has a $169.00 price target on the medical technology company’s stock, up from their prior price target of $160.00.

A number of other research analysts also recently commented on TFX. Truist Financial reaffirmed a “hold” rating and issued a $143.00 target price (up from $135.00) on shares of Teleflex in a research report on Monday, May 11th. Needham & Company LLC boosted their price target on shares of Teleflex from $147.00 to $159.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Wells Fargo & Company upped their price objective on shares of Teleflex from $130.00 to $138.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Bank of America raised Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective on the stock in a report on Monday, April 13th. Finally, Mizuho lifted their target price on Teleflex from $140.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $149.80.

Teleflex Trading Down 3.2%

TFX opened at $134.50 on Friday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.03 and a current ratio of 2.60. Teleflex has a one year low of $100.18 and a one year high of $145.00. The company has a market cap of $5.95 billion, a P/E ratio of -5.78, a PEG ratio of 0.98 and a beta of 0.81. The business’s 50-day simple moving average is $131.72 and its 200-day simple moving average is $122.54.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The firm had revenue of $570.33 million during the quarter, compared to the consensus estimate of $559.59 million. During the same period in the prior year, the company posted $3.73 earnings per share. The firm’s quarterly revenue was up 28.9% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. As a group, equities research analysts expect that Teleflex will post 7.05 EPS for the current fiscal year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Friday, August 14th will be paid a dividend of $0.34 per share. The ex-dividend date is Friday, August 14th. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. Teleflex’s dividend payout ratio is currently -5.96%.

Institutional Investors Weigh In On Teleflex

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Kelleher Financial Advisors purchased a new position in shares of Teleflex during the second quarter worth about $25,000. Banque Cantonale Vaudoise raised its stake in Teleflex by 82.5% during the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after acquiring an additional 113 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in Teleflex during the 4th quarter valued at approximately $37,000. UMB Bank n.a. lifted its position in Teleflex by 57.1% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after acquiring an additional 113 shares during the period. Finally, Sound Income Strategies LLC acquired a new stake in Teleflex during the 4th quarter worth approximately $45,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex announced a $250 million accelerated share repurchase agreement. The program should reduce the company’s share count and may support per-share earnings and investor sentiment. Teleflex Launches $250 Million Accelerated Share Repurchase
• Positive Sentiment: Second-quarter revenue rose 28.9% year over year to $570.3 million, exceeding the $559.6 million consensus estimate. Adjusted EPS of $1.76 also beat expectations of $1.28, providing evidence of better-than-expected operating performance. Teleflex Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Teleflex raised or reaffirmed its fiscal 2026 adjusted EPS outlook at $6.90 to $7.20, above the $6.70 analyst consensus. Piper Sandler maintained an Overweight rating and increased its price target to $169 from $160, signaling additional potential upside. Piper Sandler Rating and Price Target
• Neutral Sentiment: Teleflex declared a quarterly dividend of $0.34 per share, payable September 30 to shareholders of record August 14. The dividend provides ongoing shareholder returns, though its approximately 1% yield is unlikely to be a major short-term catalyst.
• Negative Sentiment: GAAP diluted EPS from continuing operations fell to $0.96 from $1.54 a year earlier, while adjusted EPS declined from $3.73. Teleflex also reported a negative net margin, which may be weighing on the stock despite the quarterly earnings beat. Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.